Aspira Womens Health Inc (AWHL)

Aspira Women’s Health Inc. is a healthcare company focused on noninvasive diagnostic testing for gynecologic diseases. Operating in the United States, it develops and commercializes AI-enabled tests used to assess the risk of malignancy in women with adnexal masses. Its commercial portfolio includes Ova1Plus, Overa, and OvaWatch, while OVAinform remains in development as a multi-marker test that combines serum proteins, clinical data, and miRNA. The company also runs Aspira Labs, a laboratory centered on biomarker-based technologies for gynecologic cancer care. Its customers include physicians, physician office laboratories, and national and regional laboratories. Aspira Women’s Health distributes products through a sales force, the Aspira Synergy platform, and marketing and distribution agreements. The company is based in Austin, Texas, and was incorporated in 1993. It previously operated under the name Vermillion, Inc., changing to its current name in 2020.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.